Role of Growth Hormone in Prostate Cancer
Abstract
We have established a GH-deficient prostate cancer model (Tag/Ghdr/dr rat) indicating that a reduction in GH and/or IGF-I can significantly inhibit prostate carcinogenesis in this model in contrast to GH wild-type controls (Probasin/Tag, Tag/Gh+/+). Tag/Gh+/+ Tag/Ghdr/dr and age-matched non-Tag controls were sacrificed at 10, 25 and 52 weeks of age. While real-time RT PCR and immunohistochemical analysis revealed the significantly increased levels of prostate GHR and the dramatically reduced levels of prostate IGF-1R (P<0.0001) in Tag/Gh+/+ during prostate cancer progression the loss of prostate GHR and the increase of IGF-1R were observed in Tag/Ghdr/dr. However there was no significant change in either serum or prostate IGF-1 level that can be correlated with prostate cancer progression or the resistance of Tag/Ghdr/dr to prostate carcinogenesis. These findings are consistent with the hypothesis that GH signaling plays a significant role in prostate carcinogenesis and suggest that GH antagonists may be effective agent against prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2007
- Accession Number
- ADA467973
Entities
People
- Steven M. Swanson
Organizations
- University of Illinois at Chicago